HALO Halozyme Therapeutics, Inc.

93.17USD-2.75%Mkt Cap: 10.92B USDP/E: 23.95

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's …

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap10.92B USD
Enterprise Value13.15B USD
Revenue (TTM)1.80B USD
Gross Profit1.27B USD
Net Income (TTM)316.89M USD
Revenue/Share15.45 USD
Last Price93.17 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees423
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)23.95
P/E (Forward)9.04
PEG—
EV/EBITDA11.53
EV/Revenue7.29
P/S6.06
P/B-197.53
EPS (TTM)4.00 USD
EPS (Forward)10.59 USD
52W Range
61.2344% of range133.96
52W High133.96 USD
52W Low61.23 USD
Profitability
Gross Margin76.27%
Oper. Margin56.67%
EBITDA Margin63.27%
Profit Margin22.69%
ROE649.18%
ROA12.55%
ROIC26.59%
ROCE34.18%
Growth
Revenue Growth39.20%
Earnings Growth40.60%
Cash Flow & Leverage
Operating CF651.56M USD
CapEx (TTM)294.74M USD
FCF Margin23.74%
FCF Yield3.92%
Net Debt2.20B USD
Net Debt/EBITDA1.93
Net Debt/FCF5.15
Balance Sheet
Debt/Equity43.89
Current Ratio3.88
Quick Ratio3.36
Book Value/Sh-0.48 USD
Cash/Share9.42 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)119.89 USD
Upside (mean)+28.7%
Target Range79.00 USD – 149.00 USD
79.00+28.7% to mean149.00
# Analysts9
Ownership
Shares Out.114.01M
Float112.70M
Insiders1.08%
Institutions115.47%
Short Interest
Short Ratio6.2d
Short % Float15.69%
Short % Out.11.98%
Shares Short13.65M
Short (prev mo.)15.30M
Technical
SMA 50114.29 (-18.5%)
SMA 20085.55 (+8.9%)
Beta0.90
S&P 52W Chg12.08%
Avg Vol (30d)2.27M
Avg Vol (10d)2.56M
Technical Indicators
RSI (14)23.5
MACD-5.7391
MACD Signal-2.5894
MACD Hist.-3.1497
BB Upper144.75 USD
BB Middle115.50 USD
BB Lower86.26 USD
BB Width50.64%
ATR (14)4.181 USD
Vol Ratio (20d)0.69x

About Halozyme Therapeutics (NASDAQ: HALO)

›

Halozyme Therapeutics (NASDAQ: HALO) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 423 employees.

The shares were at 93.17 USD on 19 November 2026, up 40.3% over 52 weeks. Its 52-week range is 61.23 USD to 133.96 USD: the price is 30.5% below the high and 52.2% above the low.

At a market capitalisation of 10.92B USD, it trades at 23.9 times trailing earnings and 9.0 times forward earnings. The median trailing P/E of its 14 largest Biotechnology peers is 34.5, a discount of 31% for HALO.

Halozyme Therapeutics reports an operating margin of 56.7% and revenue up 39.2% year over year.

Its debt exceeds its cash by 2.20B USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 9 analysts cover the stock, with an average rating of Buy; their mean price target of 119.89 USD is 28.7% above the current price. The next earnings report is expected on 16 February 2027.